July 14, 2023
Daiichi Sankyo and AstraZeneca said on July 12 that their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) earned an additional indication in China for the treatment of certain patients with HER2 low breast cancer. The drug was newly approved as...read more